NerofeTM stimulates cancer cells attraction to APC and T cells and thereby inducing the death of cancer cells.

Recent FACS results have shown a significant increase in CD86 expressing cells in three types of malignant cells treated with NerofeTM.

CD86 is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell.

Nerofe Immunotherapy - T-Cell activation following treatment
  • CD86 induction of Tumor cells by Nerofe
  • Cancer Immunotherapy - CD86 induction of tumor cells by Nerofe